Smith & Nephew PLC Sponsored ADR Stock

$29.39

2.39% yesterday

NYSE, Jun 13, 10:10 pm CET

ISIN

US83175M2052

Symbol

SNN

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

Smith & Nephew PLC Sponsored ADR Stock price

$29.39

-12.16 29.27% 5Y

NYSE, Closing price Fri, Jun 13 2025

-0.72 2.39%

ISIN

US83175M2052

Symbol

SNN

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Medical specialties

Key metrics

Market capitalization	$13.17b
Enterprise Value	$15.87b
P/E (TTM) P/E ratio	62.53
EV/FCF (TTM) EV/FCF	26.19
EV/Sales (TTM) EV/Sales	2.73
P/S ratio (TTM) P/S ratio	2.27
P/B ratio (TTM) P/B ratio	4.88
Dividend yield	2.55%
Last dividend (FY24)	$0.75
Revenue growth (TTM) Revenue growth	4.70%
Revenue (TTM) Revenue	$5.81b
EBIT (operating result TTM) EBIT	$841.00m
Free Cash Flow (TTM) Free Cash Flow	$606.00m
Cash position	$619.00m
EPS (TTM) EPS	$0.47
P/E forward	20.29
P/S forward	2.15
EV/Sales forward	2.60
Short interest	0.67%

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Get Started for Free Today

Smith & Nephew PLC Sponsored ADR Stock Analysis

Unlock Scores for Free

??

19 Analysts have issued a Smith & Nephew PLC Sponsored ADR forecast:

10x Buy

53%

9x Hold

47%

More details on Analyst Estimates Including Price Targets

19 Analysts have issued a Smith & Nephew PLC Sponsored ADR forecast:

Buy

53%

Hold

47%

Analyst Estimates with Stock Price Targets

Financial data from Smith & Nephew PLC Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	5,810 5,810	5% 5% 100%
- Direct Costs	1,764 1,764	2% 2% 30%
Gross Profit	4,046 4,046	6% 6% 70%
- Selling and Administrative Expenses	2,738 2,738	3% 3% 47%
- Research and Development Expense	289 289	15% 15% 5%
EBITDA	1,019 1,019	25% 25% 18%
- Depreciation and Amortization	178 178	14% 14% 3%
EBIT (Operating Income) EBIT	841 841	38% 38% 14%
Net Profit	412 412	57% 57% 7%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Smith & Nephew PLC Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

5 days ago

New medial stabilized insert for Smith+Nephew's LEGION™ Total Knee System designed to improve kinematics, stability and procedural versatility

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the introduction of a new medial stabilized insert for its LEGION Total Knee System (TKS). Medial stabilized inserts are seeing a steep rise in popularity, growing from 4% of Total Knee Arthroplasty procedures in 2018 to 32% in 2023.1

Neutral

GlobeNewsWire

●

18 days ago

Smith+Nephew awarded contract to provide Negative Pressure Wound Therapy systems to the United States Department of Defense

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, has been selected to provide its RENASYS◊ TOUCH Negative Pressure Wound Therapy (NPWT) Systems under a single award, 10-year* contract for up to $75 million by the U.S. Department of Defense (DoD) through the Defense Logistics Agency (DLA).

Neutral

GlobeNewsWire

●

about one month ago

Study shows patients treated with Smith+Nephew's CARTIHEAL™ AGILI-C™ Cartilage Repair Implant have an 87% lower relative risk of Total Knee Arthroplasty or Osteotomy at 4 years¹*

The CARTIHEAL Implant will be featured at the Arthroscopy Association of North America Annual Meeting (AANA 2025) this week

More Smith & Nephew PLC Sponsored ADR News

Company Profile

Smith & Nephew Plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics; Sports Medicine and ENT; and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies and ENT. The Advanced Wound Management segment comprises advanced wound care, advanced wound bioactives and advanced wound devices businesses. The company was founded by Thomas James Smith in 1856 and is headquartered in London, the United Kingdom.

Head office	United Kingdom
CEO	Deepak Nath
Employees	17,349
Founded	1856
Website	www.smith-nephew.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now